MONTREAL--(BUSINESS WIRE)--Feb. 24, 2006--Procyon Biopharma Inc. (TSX:PBP), a biotechnology company developing innovative therapeutics in the fields of cancer and HIV/AIDS, announced that at its Special Meeting of Shareholders held today, shareholders of Procyon approved the acquisition of Cellpep S.A. and the concurrent $18.1 million private placement of special warrants and units. The name change of Procyon Biopharma Inc. to Ambrilia Biopharma Inc. and the future share consolidation were also approved by Procyon' shareholders.
